A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of TROP2-Directed Antibody-Drug Conjugate LCB84, as a Single Agent and in Combination With an Anti-PD-1 Ab, in Patients With Advanced Solid Tumors
NCT #
NCT05941507
Condition(s)
Anal Cancer, Breast Cancer, Colorectal Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Lung Cancer (NSCLC), osteosarcoma, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Solid Tumor
Molecular Target(s)
TROP2
Drug Classification(s)
Antibody Drug Conjugate
Agents(s)
Adagrasib is a potent, highly selective and orally available small molecule inhibitor of a form of KRAS that harbors an oncogenic substitution mutation (G12C).mutation (G12C).
Phase(s)
I/II
Mechanism of Action
LCB84 is an anti-TROP2 ADC
Purpose
- How much of the study agent can be given alone or in combination with Pembrolizumab with an acceptable level of side effects
- The effects of the study agent alone or in combination with Pembrolizumab (good and bad)
- How much of the study agent is absorbed into the blood and how fast it is removed
- If research tests can be used in the future to predict who will benefit from LCB84
- How the study agent is acting on your body
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.